Cantor Fitzgerald Forecasts Stronger Earnings for Korro Bio

Korro Bio, Inc. (NASDAQ:KRRO) – Analysts at Cantor Fitzgerald increased their FY2025 earnings per share estimates for shares of Korro Bio in a report released on Thursday, November 13th. Cantor Fitzgerald analyst S. Seedhouse now anticipates that the company will earn ($9.70) per share for the year, up from their previous estimate of ($10.49). Cantor Fitzgerald currently has a “Neutral” rating on the stock. The consensus estimate for Korro Bio’s current full-year earnings is ($9.52) per share. Cantor Fitzgerald also issued estimates for Korro Bio’s FY2026 earnings at ($5.04) EPS.

KRRO has been the subject of a number of other research reports. Wall Street Zen raised shares of Korro Bio from a “sell” rating to a “hold” rating in a research report on Saturday. Chardan Capital reaffirmed a “neutral” rating on shares of Korro Bio in a report on Thursday, November 13th. Jones Trading cut Korro Bio from a “buy” rating to a “hold” rating in a research report on Friday. William Blair downgraded Korro Bio from an “outperform” rating to a “market perform” rating in a report on Thursday, November 13th. Finally, Raymond James Financial lowered Korro Bio from a “strong-buy” rating to a “market perform” rating in a research report on Thursday, November 13th. One equities research analyst has rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $76.00.

Korro Bio Stock Performance

Korro Bio stock opened at $6.15 on Monday. The firm’s 50-day moving average is $37.18 and its 200-day moving average is $23.38. Korro Bio has a 1 year low of $5.70 and a 1 year high of $56.69. The company has a market cap of $57.93 million, a P/E ratio of -0.65 and a beta of 2.94.

Korro Bio (NASDAQ:KRRO) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($1.92) EPS for the quarter, topping analysts’ consensus estimates of ($2.61) by $0.69. Korro Bio had a negative net margin of 1,199.53% and a negative return on equity of 68.87%. The firm had revenue of $1.09 million during the quarter, compared to the consensus estimate of $0.41 million.

Institutional Investors Weigh In On Korro Bio

Hedge funds have recently made changes to their positions in the business. Russell Investments Group Ltd. acquired a new position in shares of Korro Bio during the third quarter worth approximately $39,000. Quarry LP acquired a new stake in Korro Bio in the 1st quarter valued at approximately $35,000. CWM LLC raised its stake in Korro Bio by 391.4% during the 3rd quarter. CWM LLC now owns 2,693 shares of the company’s stock valued at $129,000 after acquiring an additional 2,145 shares in the last quarter. PNC Financial Services Group Inc. bought a new stake in Korro Bio during the 3rd quarter valued at $140,000. Finally, Wealth Forward LLC acquired a new position in Korro Bio during the 3rd quarter worth $240,000. Institutional investors own 13.18% of the company’s stock.

Korro Bio Company Profile

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).